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ABSTRACT 
Aseptic process simulation is a crucial validation technique carried out before a new product or aseptic process is introduced in the facility and also 
to prove on regular intervals that the existing manufacturing operations are carried out in a state of aseptic conditions. Aseptic process simulation 
involves conducting aseptic production using a sterile growth medium instead of actual drug solution and excipients. The processes involved in 
aseptic validation include the identification of process mechanisms, variables and control methods and that also include product, component, and 
sterilization of equipment, sanitary facilities, environmental checks and staff training on gowning procedure. 
Keywords: Aseptic Process Simulation, Validation, Media, Interventions,
This review addresses the nature of 
the study involved in aseptic process simulation, speed and number of runs, runtime, the atmospheric conditions, line speed, the media used, 
incubating and analyzing media-filled units, data interpretation, worst-case parameters, interventions, case study on interventions and the 
regulatory aspects concerned with the simulation.  
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INTRODUCTION 
An Aseptic process simulation (APS) is mimicking the steps starting from 
the dispensing of the raw material to the point products are sealed with 
sterile growth media, it starts with the formulation and ends with 
container closure; thus an APS is simply a process simulation of the exact 
formulation process of the drug product. This process simulation 
employing growth media instead of the actual drug product is also 
known as media fill [1]. Broth fills, media fills, simulation trails, are the 
synonyms for the activity undertaken as a result of the validation and 
repeated testing of the latest aseptic technology [2]. 
Media fill studies should be carried out under the worst instance 
conditions, including maximal processing and filling time and must 
include simulation of all aseptic manufacturing processes. 
There are two different situations at which the aseptic processing is 
applied:  
Preparation and filing of solutions aseptically, 
Aseptically transferring, handling and packaging of solid products 
that are not sterilized terminally in their final containers. 
The simulation media filling process is state-of-the-art to verify the 
aseptic production process in compliance with the USFDA and EU 
Guidelines. The filled container and closure are finally checked for 
microbial contamination by incubating under defined parameters. 
This is to confirm that the product is manufactured under a very less 
contamination rate. All the regulatory authorities across the globe 
state that the manufacturing procedures in the industry can be 
started only after validating aseptic process simulation [3]. 
Steps involved in media fill validation process 
Selecting suitable growth media [4] 
Demonstration of nutrient growth promotion properties 
Environmental monitoring 
Formulation of bulk media solution [5] 
Microbial performance and bio-burden examination 
Sterilization of the media using suitable sterilization techniques 
Filling of media into containers 
Filled vials must be incubated and evaluated 
Microbial requirements on validation of medial fill 
The liquid state nutrient growth medium supports the growth of 
microorganisms, which is used after the sterilization process and filled 
to mimic normal production processes that follow the steps like 
Compounding  
Sterile filtration 
In-process control checks 
Sterilization of the manufacturing process 
Sterilization of materials: garments, primary containers, filling 
equipment by using various sterilization techniques like autoclaving, 
dry heat or gamma radiation [6]. 
Cleaning, sterilization process and filling [7]. 
The control checks performed to maintain the hygienic state of the 
manufacturing process are:  
HVAC validation  
Qualification of personnel 
Gas supply systems 
Water handling systems 
Equipment washing and sterilization [2] 
Purpose of aseptic process simulation 
The food and drug administration states that an APS must validate the 
aseptic method by using the growth medium, which is both handled 
and exposed in an identical way to personnel, machinery, surfaces and 
environmental conditions. The purpose of APS by the parenteral drug 
association is to certify and qualify aseptic processing personnel [8]. 
The purpose of the simulation is to provide the probability of 
microbiological contamination caused in a specific aseptic process. 
The ampules or vials are filled with medium. The packed containers 
are incubated and the numbers of contaminated units are rated 
against the number of uncontaminated units, thus providing an 
index of the probability of contamination (the contaminated 
proportion) resulting from the aseptic phase [3]. 
The major microbial contaminations in aseptic processing are 
personnel contaminants, human error, non-routine activity, aseptic 
assembly, mechanical failure, improper sanitization, material 
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transfers, surface contamination, airborne contamination, Failure of 
0.2µ filter, failure of HEPA filters, improper sterilization [4, 8]. 
Study analysis during aseptic process simulation 
Pre aseptic process simulation activity 
Before starting the APS activity, the Pre aseptic process checks must 
be conducted to avoid the microbial growth, entry of particulate into 
an aseptic area and also conducting of swab sampling before the 
equipment starts with its manufacturing process.  
Microbial monitoring 
In and around high operator activity areas, microbial control should 
be carried out.
Particulate monitoring 
 It is not uncommon to see plate settlements and 
positions of air samples far away from those regions. A standard 
check is the location of settle plates on the rear of the filling machine 
where there is little or no operator involved. 
Routine particle tracking is useful for the rapid identification of 
major air cleanliness deviations from eligible processing 
requirements (e. g. destination of clean areas) [5, 9]. The particulate 
monitoring involves the monitoring of the non-viable and viable 
particles which come under environmental monitoring. If the 
movement of personnel is more in the aseptic area, particulate 
matter increases. 
Swab sampling 
The cleanroom areas must be monitored to regulate the 
microbiological cleanliness of Grades A to D during manufacturing. 
Monitoring should be periodic, where aseptic operations are 
performed using processes like settle plates, surface, and volumetric 
air sampling 
During the aseptic process simulation activity 
[6, 10]. The swab sampling is done before the aseptic 
processing activity starts. Sampling is mainly taken from the 
equipment that is used in the manufacturing process. Generally, the 
sampling procedure is done by both in-process quality assurance 
personnel and the microbiologist. Microbiologist checks the growth of 
micro-organism then assures with the next process of manufacturing.  
During the manufacturing process, additional precautions need to be 
taken to mimic the exact interventions that might the aseptic 
condition of the manufacturing facility. Some of the factors include, 
Gowning procedure 
Gowing is important in aseptic processes to prevent contamination 
[7, 11]. The training of the employees for gowning practices should 
be assisted by an observer who visits the aseptic cleanroom to 
confirm that correct procedures are practiced [8, 12]. The analyst 
must wear a clean laboratory suite, sterile sleeves and sterile gloves 
when doing the examination. Disinfected gloves must be used for the 
opening and handling of the sample units [9, 13]. The gowning 
practice in the aseptic manufacturing area must be practiced as per 
the following fig. 1 given below 
 
 
Fig. 1: Gowing procedure [10, 14] 
Disinfection 
It is important to determine the suitability and efficacy of the 
disinfecting agents and its procedure. The efficacy of the 
disinfectants and procedures should be evaluated in terms of their 
ability to ensure that possible contaminants are extracted from 
surfaces sufficiently [15]. To avoid contamination, disinfectants 
must be sterile, properly maintained in suitable containers and not 
used for longer than the duration specified in the written protocol 
[5, 9]. 
Personnel movement 
While concerns of cleanroom apparel are usually reduced in an 
isolator process, it is not possible to ignore the contamination risk 
posed by manual factors. 
Post aseptic process simulation activity 
Isolation procedures usually require 
occasional or even regular use of one or more gloves to manipulate 
aseptically and manage the material transfer to and from the 
isolator. To decrease the contamination of the product, personnel 
movements must be avoided in the aseptic manufacturing area. 
Improper personnel movement can lead to the risk of 
contamination. 
After completing the APS activity, the post aseptic process checks 
must be conducted to evaluate the possibility of microbial growth, 
entry of particulates into an aseptic area and also conducting of 
swab sampling after the manufacturing process. Performing this 
post-simulation activity gives a better picture of possible 
contaminants at the time of manufacturing.  
Factors to be considered during aseptic process simulation 
Water system qualification 
By using purified water, water for injection must be produced.  
They must be stored and distributed properly to prevent microbial 
growth by maintaining constant circulation at a temperature above 
70 ℃. 
Different methods like distillation, post reverse osmosis, ultra-
filtration and Nanofiltration are the techniques used for the 
preparation of water for injection. 
By considering seasonal variation, the water system must be 
approved to control relevant levels of microbiological growth. 
Turbulent water flow must be maintained through the pipes to 
prevent microbial adhesion [16]. 
Pure steam qualification 
For pure steam production, sterilized water with lower levels of 
endotoxins must be used. 
Compressed air system qualification 
Steam used to sterilize shall be of appropriate portion and must not 
contain contaminants that are capable of contaminating the 
equipment or substance at a point.  
The primary product or container surface in direct contact with 
compressed gasses must have related components, particulate and 
microbiological purity without oil with adequate requirements for 
dew points and acceptable pharmacopeia. At the point of use 
compressed gases should be filtered via sterilization filter with a 
determined pore size of 0.22 µm. 
Elements involved in aseptic process simulation 
There are various aspects to be considered to successfully 
conduct an APS validation study, the parameters to be selected 
can be based on the Risk assessment carried out in determining 
the factors affecting the aseptic filling [17]. Fig. 2 represents a 
few of the factors which might be considered in the process of 
validation. 
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Fig. 2: Elements in APS [9] 
 
Aseptic process simulation study design 
The media fill program includes risk factors for the contamination 
that happens on a manufacturing line, precisely measures the state 
of method control. Media fill studies must carefully pretend aseptic 
developed processes including, worst-
Issues relating to the longest appropriate processing line run will 
lead to a risk of contamination. (Tiredness of operator can be given 
as an example) 
case actions, circumstances 
that offer a task to aseptic operations. Recommendations and issues 
that are provided by the FDA are [18]. 
Aseptic assembly of equipment’s 
Number of activities and their associated personnel 
Weight checks 
Speediness and structure  
Container closure system 
Aseptic sample gathering 
Frequency of media fills  
In the process simulation procedure, the frequency of media fills 
should be fixed based on risk assessment.  
Initial process simulation  
For new facilities, equipment, filling line and container design, initial 
performance testing is performed. As per Japanese Pharmacopoeia, 
Media fill testing shall be conducted with appropriate liquefied 
products that have been filled into units that correctly represent a 
real one-manufacture filling line with at least three repeat runs on 
different days. For bulk product, the check should be carried out 
using the bulk product quantity of one production unit [19, 20]. 
Repeated process simulation 
Periodically conduct a media filling requalification at each work change 
for the filling line. Aseptic processing workers must be qualified to carry 
out aseptic processing and participate in media filling.  
In the case of facilities and equipment improvements 
(interchangeable parts do not need requalification), adjustments in 
personnel involved in essential aseptic manufacturing (e. g. new 
crews) discrepancies in environmental test results, or a product 
sterility check indicating contaminated goods, the correct number of 
media fill runs is performed in the same manner as in the original 
performance testing before the adjustment [19]. 
If filling lines are not used for more than six months, then perform 
enough medium fills in the same way as the initial output 
certification before resuming the filling lines. 
Duration of runs 
In media fill design, the length of aseptic handling operation is the 
main consideration. While the utmost realistic simulation model 
should be the maximum lot size and length since the actual 
manufacturing process is more closely simulated, other acceptable 
models may be reasonable [21]. 
The time needed to implement factors and initiatives shall be measu
red according to the duration of the media fill, as real aseptic 
processing activity duration must be taken into account.  
Commonly occurring interventions must be simulated routinely, 
while those rarely occurring may be simulated periodically.  
The FDA suggests opening unsealed containers to partial chamber 
evaluation in a manner that would mirror the protocol for 
lyophilization operations.  
Vials must not be frozen, and precautionary measures must be 
reserved to certify that the medium is leftover in an aerobic manner 
to escape micro-organism growth being possibly inhibited [9, 22]. 
Size of runs  
During the simulation phase, the number of units performed must 
depend on the risk of contamination of the specified process and be 
adequate to simulate activities representative of the production 
process. 
An appropriate initial point for run size is in between the series from 
5,000 to 10,000 units. The number of filled units must be at least 
equivalent to the regular lot size produced in the manufacturing line 
for operations with an output of sizes below 5000 [9]. 
When the potential for contamination is greater based on process 
design, several units with full batch size must be used. An isolator 
cycle may have a smaller risk of contamination as a result of the lack 
of direct interference by humans and may calculate with fewer units 
as a percentage of total operations. 
Because several batches are created over various shifts or outputs 
and an exceptionally high number of units, media filling is especially 
important. In designing the simulation to accurately cover the 
Hemanth et al. 
Int J App Pharm, Vol 12, Issue 4, 2020, 17-23 
20 
circumstances and any potential risks associated with the larger 
operation, these considerations are carefully considered [23-25]. 
Line speed  
Environmental conditions 
The media fill system will discuss appropriately the line speed range 
used during development, but the media fill run will determine a 
single line speed and validate the chosen speed [9]. For instance, the 
use of high line speed is frequently more acceptable when assessing 
the production method influenced by repetitive interventions or a 
considerable degree of physical manipulation. Using slow line speed 
is typically suitable for testing production processes with extended 
sterile drug product exposure and containers/closures [18, 23]. 
Monitoring of non-viable particles 
Monitoring of the chosen location must be observed to ensure the 
worst-case conditions. 
The room monitoring is done where the activity of the operator is 
more and the particulate counts in the location must be performed. 
The checking of the environmental counts must be performed 
adjacent to the filling zone and to investigate the operator activity 
within these areas [21]. 
The air from the HEPA filter is monitored with sampling probes. 
The sampling device must not compromise the airflow in the critical 
zone. 
The worst-case conditions are identified and confirmed by the 
validation process. 
By process simulation tests these are reconfirmed [18, 26].  
Media 
Soybean casein digest medium (SCDM), which promotes gram-
positive and gram-negative growth of bacteria, yeast and mold must 
be used [9]
In special circumstances, consideration should be given to the use of 
anaerobic growth media (e. g. fluid thioglycollate medium).  
. 
Environmental inspection and sterility checking can be replaced or 
applied to the growth-promoting factor. 
Growth-promoting units must be inoculated with a<100 CFU 
challenge. Nevertheless, if the growth promotion test fails, it is 
important to examine the root of any contamination detected during 
the simulation, immediately repeat the media [13]
The manufacturing process must be simulated precisely using media 
and circumstances that minimize microbiological contamination. 
.  
The below fig. 3 indicates the initial stage of the test regarding the 
SCDM with no growth of microorganisms and fig. 4 shows the 
growth of microorganisms after completion of inoculation and the 
incubation. A growth indicates that the media is supporting the 
growth of organisms and the media can be chosen for the fill studies. 
The individual unit has to be filled with an acceptable quantity and 
type of microbial growth medium to detect microbial growth 
visually on the inner surfaces of the container (when the unit is 
flipped or thoroughly whirled) [14].  
 
 
Fig. 3: Soybean casein digest medium before inoculation [27] 
 
 
Fig. 4: Growth of microorganism in soybean casein digest 
medium after inoculation and incubation [28] 
 
Incubation and examination of filled units 
Incubate all the media fill units at 20 to 25 ℃ for 7 d. The incubation 
rage must be within 22.5±2.5 ℃ [29]. 
After the completion of 7 d at the 20 to 25 ℃, for the next 7 d, 
containers are placed in an inverted position and incubate them at 
30 to 35℃. The temperature incubation range must be maintained 
within 32.5±2.5 ℃ [30]. 
After day 3, day 7, day 10 and day 14, the qualified microbiologist 
examines each Filled media unit. 
During the observation, all the suspected units are sent for 
investigation to QC microbiologist.  
All suspicious units recognized during the investigation must be 
carried to the instant consideration of the QC microbiologist. 
QC microbiologist may recommend exchanging transparent 
containers for amber or other opaque containers to detect microbial 
growth easily [9].  
  
Units that are not found to have faults linked to integrity must be 
incubated and units lacking integrity are rejected. 
Interpretation of data 
Table 1: Interpretation of data 
Range Acceptance criteria Reference 
If the range of filling is less than 
5000 units 
The units determined must be of no contamination. [5] 
When filling range is in between 
5000-10,000 units 
•Including the consideration of repeat, media fill only one suspected unit should be found 
in an investigation. 
•Two contaminated units are deemed cause for revalidation following an investigation. 
[15] 
If the filling range is more than 
10,000 units 
•In an investigation only one contaminated unit must be found. 
•Cause for revalidation involves the consideration of two contaminated units. 
[25] 
The below image gives the information regarding the clear vial and the contaminated vial 
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5: Images of contaminated and uncontaminated vials [32] 
Worst-case parameters or conditions 
Worst-case scenarios in the sense of aseptic processes do not 
essentially mean the worst-case likely. To get technical benefits after 
the analysis, the worst-case scenarios must be used in the simulation 
readings of the process [21]. 
The simulation design will suit the routine ase
Worst
ptic manufacturing 
process as closely as possible and should include all relevant 
essential development steps. Reasonable combinations of container 
size and aperture, as well as transmission line speed, should be used. 
The simulation test for the process will represent a worst-case 
scenario and include all manipulations and procedures that are 
likely to be encountered during a changeover.  
-
Longest fill duration 
case parameters are defined for the machines which are used 
as shared equipment’s which involves [26] 
Wide container opening 
The longest exposure time of open container  
Case study on considering the worst-case in media fills  
Do the minimum and the maximum number of operators in the 
cleanroom considered as the worst-case?  
Yes, more number of operators is a large source of microbial 
contamination, but a limited number can increase operator activity 
and reduces focus. Each can be seen as the worst-case.  
What can be the worst-case between the larger containers and 
smaller containers?  
Both might be considered as worst-cases because the chance of 
contamination is more into the larger containers having wider 
openings and throughout the transportation and filling process, 
smaller containers are not stable. 
Which can be chosen as the worst-case slowest or fast-fill speed? 
In this case, the slower filling represents more risk contamination 
before sealing, the faster filling can represent the more mechanical 
movement, potential airflow disruption, and the transport of 
containers is unsafe.  
Intervention monitoring 
From these parameters, a single set of worst-cases can’t be chosen, 
for this reason in the process simulation analysis, all possible worst-
case configurations must be included [18].  
The interventions are classified as:  
Interventions caused by humans in aseptic processing 
Routine Interventions 
Non-routine interventions [33] 
Interventions caused by humans in aseptic processing 
The interventions caused by humans have more potential impact on 
aseptic processing when compared with other factors contamination.  
Room design, sterilization processes, environmental sanitation, 
heating and ventilation are the sources that provide less 
contamination. 
The organisms present on humans are in millions and these 
microorganisms are spread continuously to their gowning materials 
and their surroundings because of improper gowning  
Improper personnel Hygiene 
Eating, drinking, smoking on-premises, etc. 
Routine interventions 
These are the activities that occur in every batch and can also be 
named as typical routine interventions 
Equipment must be aseptically assembled  
Start-up or launch of the part  
Weight or volume change of the initial fill  
Periodic component replenishment  
Periodic refilling of the components  
Periodic filling and measuring weight or volume  
Correction of volume or fill weight  
Monitoring of environmental conditions 
Operator breaks and meals  
The change in shift of the operator 
A Sampling of the product 
The integrity of the filter is tested 
Replacing product container 
Adjustment in a component [8] 
Non-routine interventions 
These interventions are not part of every batch, but they are 
predominantly corrective. 
Avoid clumping or misfeed of the stopper 
Collapsed, wrecked, or blocked containers  
Remove faulty seals on containers 
Leakage of the product must be avoided 
Product Filter change 
Sensor adjustments or replacement 
Replace the filling indicator  
Additional fill-pump must be used alternatively 
Schedule changes 
Changes to Conveyor or guide rail [31, 33] 
Case studies on interventions 
Case study 1 
Interventions produced by personnel 
Background 
More than half of the units that are run by media fill were found to 
be microbiologically contaminated. Minor changes were made to the 
process and three media fills were carried out again. A high level of 
contamination was yielded during the second media fill run. Isolates 
in both failures were common skin borne microbes. 
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Issues found by cGMP 
cGMP observes that there is an improper gowning practice followed 
by the personnel in the aseptic area. The problem that is found in the 
contamination was a design flaw in the gown. 
Action 
The firm corrected the deficiencies recognized in the gowning 
practice. 
Case study 2 
Assuring container-closure integrity throughout manufacturing  
Background 
Parenteral drug products have been found infected with 
Enterobacter cloacae and analyses of sealed vials have improved 
Xanthomonas maltophilia microorganism. 
Issues found by cGMP 
They found that there is a container closure integrity problem. The 
sealed glass vials that had been passed through secondary packaging 
are dropped from the bulk pallets by the operator. In the cleaning 
process of the spillage product, the personnel washed the unbroken 
vials with portable sink water. 
Root cause 
The problem that is identified in this case is packaging and labelling. 
Root cause observed was that improper handling of the sealed glass 
vials and harsh treatment of these may result in small cracks on 
vials. The microorganisms enter the product when the vials are 
washed with potable water. The water samples are collected by FDA 
from the firm and the same organism E. cloacae was identified [34].  
CONCLUSION 
FUNDING 
The simulation process should stimulate the production process, 
where the aseptic activities are performed, from the establishment 
of vial assemblies through to the transfer of the bulk drug from the 
sterilizing filter to the finished containers that are ready for release. 
Regulatory authorities very closely monitor the media fill 
qualification studies as they form the base for future commercially 
manufactured products. Any failure to qualify media fills is 
considered as a serious issue and costs a lot to the manufactures as 
the production needs to be halted until the firm clears the media fill 
study. So at most, care has to be taken while planning, designing and 
executing media fill studies, which can be achieved through 
experience and proper execution.  
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